Erythrodermic psoriasis after discontinuation of ixekizumab

Erythrodermic psoriasis after discontinuation of ixekizumab

INTRODUCTION Erythroderma is defined as generalized redness and scaling affecting more than 90% of the skin surface and often accompanied by systemic complications such as hypothermia, dehydration, and electrolyte imbalance. Treatment is targeted at the underlying cause, and preexisting dermatoses are identified in 65% of patients. Psoriasis is the most common underlying disease in erythrodermi...

Erythrodermic Psoriasis Treated with Apremilast

Erythroderma is a rare potentially deadly exfoliative dermatitis characterized by diffuse cutaneous erythema which may be associated with multi-organ dysfunction. Therefore, it is imperative to recognize and treat it promptly. Erythrodermic psoriasis is the most common form of erythroderma. Management of this condition is largely based on aggressive supportive care and the use of anti-inflammat...

Erythrodermic psoriasis: pathophysiology and current treatment perspectives

Erythrodermic psoriasis (EP) is a rare and severe variant of psoriasis vulgaris, with an estimated prevalence of 1%-2.25% among psoriatic patients. The condition presents with distinct histopathologic and clinical findings, which include a generalized inflammatory erythema involving at least 75% of the body surface area. The pathogenesis of EP is not well understood; however, several studies su...

Discontinuation of methotrexate in psoriasis.

Ustekinumab Treatment of Erythrodermic Psoriasis Occurring after Physical Stress: A Report of Two Cases

Erythrodermic psoriasis (EP) is a severe form of psoriasis precipitated by numerous factors, including physical stress, infections, and drugs. The disease represents a therapeutic challenge, and little is known about its response to ustekinumab. Though the efficacy of ustekinumab has been extensively studied in chronic plaque psoriasis, no trials have been carried out in EP. We report the case ...